REFERENCE

1.Micheal J. Rathbone, Jonathan Hadgraft, Micheal S. Roberts , Majella E. Lane;”

Modified Release drug delivery System”, II Edtion, Vol-I, Informa Healthcare, USA,
2008, 343-345.
SITE {http://books.google.co.in/books?
id=56TeYRI3LUMC&printsec=frontcover&source=gbs_v2_summary_r&cad=0#v=one
page&q=&f=false}

2. http://en.wikipedia.org/wiki/Colon_%28anatomy%29
1. http://definr.com/large+intestine
2. http://wiki.answers.com/Q/What_are_the_lengths_of_the_different_parts_of_the_
colon
3. Mayo Clinic Staff (2006-10-13). "Redundant colon: A health concern?". Ask a
Digestive System Specialist. MayoClinic.com.
http://www.mayoclinic.com/health/redundant-colon/AN00239/rss=1. Retrieved
2007-06-11.
4. Lichtenstein, Gary R.; Peter D. Park, William B. Long, Gregory G. Ginsberg,
Michael L. Kochman (18 August 1998). "Use of a Push Enteroscope Improves
Ability to Perform Total Colonoscopy in Previously Unsuccessful Attempts at
Colonoscopy in Adult Patients". The American Journal of Gastroenterology 94
(1): 187. doi:10.1111/j.1572-0241.1999.00794.x. PMID 9934753. Note:Single
use PDF copy provided free by Blackwell Publishing for purposes of Wikipedia
content enrichment.

3. http://www.pharmainfo.net/reviews/colon-targeted-pulsatile-drug-delivery-review

1. Gennaro AR , ed. Remington: The Science and Practice of Pharmacy. 20th ed.
USA : Lippincott, Williams & Wilkins; 2000, 20:903-905.
2. Bussemer T, Otto I, Bodmeier R. Pulsatile drug delivery systems. Crit Rev Ther
Drug Carrier Syst. 2001;18(5):433-58.
3. Review. Das NG, Das SK. Controlled release of oral dosage forms, formulation,
finish, and fill. www.pharmtech.com. 2003;10-16.
4. Umang Pharmatech Pvt. Ltd., Umang offers Road to Pelletisation through
spher’odization. Express Pharma Pulse, 2000.
5. Gurny R, Junginger HE, Peppas N. Pulsatile Drug Delivery: Current Applications
and Future Trends. Stuttgart , Germany : Wissenschaftliche
Verlagsgesellschaft;1993.
6. Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric
emptying of meals in humans. Gastroenterol. 1987;93(3):515-518.
7. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm
Pharmacol. 1999;51:887-890.
8. Dethlefsen U, Repges R. Ein neues therapieprinzip bei nächtlichem asthma. Med
Klinik. 1985;80:44-47.

1
9. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug
delivery systems. J Pharm Pharmaceut Sci. 2003;6(1):33-66.
10. Lachman L, Lieberman HA, Kanig JL, The Theory and Practice of Industrial
Pharmacy. Vol. 3. India : Verghese Publishing House; 1991.
11. Chang R-K, Guo X, Burside BA, Couch RA, Rudnic EM. Formulation
approaches for oral pulsatile drug delivery. Amer Pharma Rev. 1999;2(1):51-57.
12. Petereit HU. Pulsed release drug delivery. www.iptonline.com. 2003:101-104.
13. Vinay kumar et al. Basic physiology. 5 th editon, W>B> saundres componey,
1992, 21.
14. Chang R.K. et al. American pharmaceutical review, 1999,21.
15. Lammer B. J Pharmacol. 51, 1999, 887.
16. Wilding IR, Davis SS, Bakhshaee M et al. Pharm Res, 9:654-657, 1992.
17. McNeil ME, Rashid A, Stevens HNE. Dispensing Device. WO Patent No.
90/09168 (1990).
18. Wilding IR, Davis SS, Bakhshaee M, Stevens HNE, Sparrow RA, Brennan J.
Gastrointestinal transit and systemic absorption of captopril from a pulsed-release
formulation. Pharm Res.1992;9:654-657.
19. Saeger H, Virley P. Pulsincap& Mac226: Pulsed-Release Dosage Form. Product
information from Scherer DDS, Ltd; 2004.
20. Binns J, Stevens HNE, McEwen J, Pritchard G, Brewer FM, Clarke A, Johnson
ES, McMillan I. The tolerability of multiple oral doses of Pulsincap & Mac226
capsules in healthy volunteers. J Control Rel. 1996;38:151-158.
21. Krögel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body
controlled by an erodible plug. Pharm Res. 1998;15(3):474-481.
22.  Krögel I, Bodmeier R. Evaluation of an enzyme-containing capsular shaped
pulsatile drug delivery system. Pharm Res. 1999;16(9):1424-1429.
23.  Crison JR, Siersma PR, Taylor MD, Amidon GL. Programmable oral release
technology, Port Systems & Mac226: a novel dosage form for time and site
specific oral drug delivery. Proceed Intern Symp Control Rel Bioact Mater.
1995;22:278-279.
24. Crison JR, Siersma PR, Amidon GL. A novel programmable oral release
technology for delivering drugs: human feasibility testing using gamma
scintigraphy. Proceed Intern Symp Control Rel Bioact Mater. 1996;23:51-52.
25. Crison JR, Vieira ML, Kim J-S, Siersma C, Amidon GL. Pulse delivery of
methylphenidate in dogs using an osmotic drug delivery system. Proceed Intern
Symp Control Rel Bioact Mater. 2001;28:6101.
26.  Pollock-Dove C, Dong L, Wong P. A new system to deliver a delayed bolus
of liquid drug formulation. Proceed Intern Symp Control Rel Bioact Mater.
2001;28:6033.
27. Linkwitz A, Magruder JA, Merrill S. Osmotically Driven Delivery Device with
Expandable Orifice for Pulsatile Delivery Effect. US Patent No. 5,318,558; 1994.
28. Linkwitz A, Magruder JA, Merrill S. Osmotically Driven Delivery Device with
Expandable Orifice for Pulsatile Delivery Effect. US Patent No. 5,221,278; 1993.
29. Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically Driven Delivery Devices
with Pulsatile Effect. US Patent No. 5209746; 1993.

2
30. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Composition Comprising
Salbutamol. US Patent No. 4751071; 1988.
31. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Constant Release System with
Pulsed Release. US Patent No. 4777049; 1988.
32. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Composition Comprising a
Therapeutic Agent and a Modulating Agent. US Patent No. 4851229; 1989.
33. Pozzi F, Furlani P. Orale Feste Pharmazeutische Darreichungsform Mit
Programmierter Freisetzung. DE Patent No. 4122039; 1992

5. http://www.jyoungpharm.in/article.asp?issn=0975- 1483;year=2009; volume=1;

issue=1;spage =13;epage=19;aulast=Jose.

34. Jung YJ, Kim HH, Kim YK, Han SK. Synthesis and evaluation of 5-Amino
salicylglycine as a potential colon specific prodrug of 5-ASA. Arch Pharmacol
Res 1998;21:174-8.     
35. Simpkins JW, Smulkowski M, Dixon R, Tuttle R. Evidence for the delivery of
narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp
Ther 1988;244:195-205.  
36. Cui N, Friend DR, Fedorak RN. A Budesonide prodrug accelerates treatment of
colitis in rats. Gut 1994;35:1439-46.
37. Haeberlin B, Rubas W, Nolen HW, Friend DR. In vitro evaluation of
dexamethasone-b-D-glucuronide for colon-specific drug delivery. Pharm Res
1993;10:1553-62.       
38. Friend DR, Chang GW. Drug Glycosides: Potential prodrug for colon-specific
drug delivery. J Med Chem 1985;28:51-7.  
39. Andrew D, Thomas N. Synthesis and chemical stability of glucocorticoid-dextran
esters: potential prodrugs for colon specific delivery. Int Journal of Pharm
1993;92:105-14.